Contact Us

Beilu Pharma's Iopamidol Injection passed the Consistency Evaluation of Generic Drugs!


Iopamidol Injection

Recently, Beilu Pharma received the “Approval Notice for Supplementary Drug Application” for two specifications of Iopamidol Injection issued by the NMPA (Notice No.: 2022B00641, 2022B00642). Following Iohexol Injection, Iodixanol Injection and Gadopentetate Dimeglumine Injection, it is the company’s fourth Contrast Agent product passed the quality and efficacy consistency evaluation of generic drugs.

Related Products
Related News